scholarly journals Multiple actions of parathyroid hormone‐related protein in breast cancer bone metastasis

2019 ◽  
Author(s):  
T. John Martin ◽  
Rachelle W. Johnson
Keyword(s):  
Breast Cancer ◽  
Parathyroid Hormone ◽  
Bone Metastasis ◽  
Related Protein ◽  
Parathyroid Hormone Related Protein ◽  
Breast Cancer Bone Metastasis

Obtusifolin Suppresses Phthalate Esters-Induced Breast Cancer Bone Metastasis by Targeting Parathyroid Hormone-Related Protein

2014 ◽  
Vol 62 (49) ◽  
pp. 11933-11940 ◽  
Author(s):  
Ya-Ling Hsu ◽  
Eing-Mei Tsai ◽  
Ming-Feng Hou ◽  
Tsu-Nai Wang ◽  
Jen-Yu Hung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Parathyroid Hormone ◽  
Bone Metastasis ◽  
Phthalate Esters ◽  
Related Protein ◽  
Parathyroid Hormone Related Protein ◽  
Breast Cancer Bone Metastasis

scholarly journals Parathyroid Hormone-related Protein Regulates Tumor-relevant Genes in Breast Cancer Cells

2006 ◽  
Vol 281 (21) ◽  
pp. 14563-14572 ◽  
Author(s):  
Angela Dittmer ◽  
Martina Vetter ◽  
Dario Schunke ◽  
Paul N. Span ◽  
Fred Sweep ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Parathyroid Hormone ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Related Protein ◽  
Parathyroid Hormone Related Protein

scholarly journals Parathyroid hormone related protein and hypercalcaemia in breast cancer.

BMJ ◽  
1991 ◽  
Vol 303 (6816) ◽  
pp. 1506-1509 ◽  
Author(s):  
N J Bundred ◽  
W A Ratcliffe ◽  
R A Walker ◽  
S Coley ◽  
J M Morrison ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Parathyroid Hormone ◽  
Related Protein ◽  
Parathyroid Hormone Related Protein

PTHrP(12-48) for the diagnosis of breast cancer bone metastasis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21039-e21039
Author(s):  
Charity L. Washam ◽  
Stephanie D. Byrum ◽  
Kim Leitzel ◽  
Ali M. Suhail ◽  
Allan Lipton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Logistic Regression ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Statistical Significance ◽  
Breast Cancer Patients ◽  
Parathyroid Hormone Related Protein ◽  
Increased Risk ◽  
Breast Cancer Bone Metastasis

e21039 Background: Bone metastasis of breast cancer significantly compromises patient morbidity and mortality. Currently, no reliable methods detect or predict patients at increased risk for developing bone metastasis. We utilized 3 independent cohorts of breast cancer patients to validate a highly discriminatory plasma-based proteomic profile that identifies breast cancer bone metastasis. The identity of the most discriminatory protein component identified was a parathyroid hormone-related protein fragment, PTHrP(12-48). Methods: Plasma samples collected from 21 breast cancer patients with clinical evidence of a bone metastasis and 21 patients with no evidence of bone metastasis from time of diagnosis to clinical outcome were evaluated. A novel mass spectrometry-based assay using human serum spiked with synthetic PTHrP(12-48) was used to measure PTHrP(12-48) concentrations (pg/μl). Statistical significance was assessed by one-way ANOVA. ROC curves evaluated the diagnostic potential of PTHrP(12-48) and a simple logistic regression derived from the combined measurement of PTHrP(12-48) and NTx. Results: PTHrP(12-48) concentrations ranged between 11.6 and 92.1 pg/μl in bone metastasis patients and between 4.5 and 34.2 pg/μl in patients without bone metastases. PTHrP(12-48) was significantly increased in bone metastasis plasma (p < 0.05). No significant correlation was identified between PTHrP(12-48) and NTx. ROC analysis of PTHrP(12-48), threshold 18 pg/μl, classified the two groups with high accuracy. Class prediction by the PTHrP(12-48)/NTx logistic regression model increased diagnostic specificity. Conclusions: The measurement of PTHrP(12-48) in patient plasma has potential as a viable clinical measure of bone metastasis. In combination with serum NTx, PTHrP(12-48) may assist in identifying bone metastases in patients presenting with low to normal bone turnover markers.

Sign in / Sign up

Export Citation Format

Share Document